Aclaris Therapeutics Inc (fra:8AT) Share Price

Company Profile

Business description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Contact
701 Lee Road
Suite 103
WaynePA19087
USA
T: +1 484 324-7933
E: [email protected]
https://www.aclaristx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
64

Recommended

Shares have dropped 20% in the previous year due to concerns about tariffs.

Esther Holloway | 27 October 2025

Higher gold prices are making a difference to the bottom line but investors overly optimistic.

Jon Mills, CFA | 27 October 2025

We see faster cloud growth and improved longer-term profitability for Alphabet.

Malik Ahmed Khan, CFA | 25 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,295.80	26.20	-0.28%
CAC 40	8,233.06	6.12	-0.07%
DAX 40	24,291.82	16.96	-0.07%
Dow JONES (US)	47,544.59	337.47	0.71%
FTSE 100	9,667.43	13.61	0.14%
HKSE	26,346.14	87.56	-0.33%
NASDAQ	23,637.46	432.59	1.86%
Nikkei 225	50,219.18	293.14	-0.58%
NZX 50 Index	13,402.66	11.07	0.08%
S&P 500	6,875.16	83.47	1.23%
S&P/ASX 200	9,012.50	16.30	-0.18%
SSE Composite Index	3,988.22	8.72	-0.22%